USFDA GRANTS APPROVAL TO CADILA HEALTHCARE’S BRIVARACETAM TABLETS

Highlights
• Zydus Cadila has currently received 319 approvals and has filed over 400 ANDAs ever since it started filing process in FY 2003-04
• Following the announcement, shares of Cadila Healthcare plunged 1.56% to Rs 654.50 on the Bombay Stock Exchange

The US Food and Drug Administration (FDA) has granted a tentative approval to Cadila Healthcare to sell Brivaracetam tablets, in the strengths of 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg. These tablets are used in the treatment of partial-onset of seizures (epilepsy) and will be manufactured at the Zydus Cadila group’s formulation manufacturing facility located in SEZ, in Ahmedabad, Gujarat.
According to an announcement made by Zydus Cadila, it has currently received 319 approvals and has filed over 400 ANDAs ever since it started filing process in FY 2003-04.
As per the numbers posted by the pharma group, the net profit went up by 76.9% to Rs 731.60 crore on 3.6% increase in net sales to Rs 3,756.20 crore in Q4 March 2021 over Q4 March 2020.
Following the announcement, shares of Cadila Healthcare plunged 1.56% to Rs 654.50 on the Bombay Stock Exchange.

Leave a Reply

Your email address will not be published. Required fields are marked *